HomeStock ScreenerSandu Pharmaceuticals

Sandu Pharmaceuticals Share Price | Sandu Pharmaceuticals Stock Screener

SANDUPHQ Pharmaceuticals
Share Price BSE
₹39.33
▲ 0.91 (2.37%)
2026-05-21 00:00:00
As of May 21, 2026, the Sandu Pharmaceuticals share price (BSE: SANDUPHQ) is ₹39.33, up 2.37% from the previous close, with shares trading between ₹37.00 and ₹40.00, and a 52-week range of ₹30.52–₹56.91. Check SANDUPHQ 52-week performance for the annual price range and momentum. Use the Sandu Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Sandu Pharmaceuticals Market Cap ₹37.14 Cr.
SANDUPHQ P/E Ratio (TTM) 23.10
Sandu Pharmaceuticals P/B Ratio 1.07
EPS (TTM) ₹1.60
Dividend Yield 2.15%
Debt to Equity -
SANDUPHQ 52 Week High ₹56.91
Sandu Pharmaceuticals 52 Week Low ₹30.52
Operating Margin 3.00%
Profit Margin -
SANDUPHQ Revenue (TTM) ₹14.00
EBITDA ₹1.00
Net Income -
Total Assets ₹56.00
Total Equity ₹42.00

Sandu Pharmaceuticals Share Price Chart

Screen Sandu Pharmaceuticals share price with an interactive chart. Analyse SANDUPHQ price trends and volatility across different timeframes.

Sandu Pharmaceuticals Company Profile - Fundamental Screener

Screen Sandu Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SANDUPHQ shares.
Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E
ISIN INE751D01014

Sandu Pharmaceuticals Balance Sheet Screener

Screen SANDUPHQ balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
Item 2025 2024 2023
Assets
Total Assets 56 52 54
Current Assets 26 22 26
Fixed Assets 18 18 17
Liabilities
Total Liabilities 0 0 0
Current Liabilities 2 1 1
Non-Current Liabilities 0 0 0
Shareholders' Equity
Total Equity 42 41 39
Share Capital 10 10 10
Reserves & Surplus 32 31 30

Sandu Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis

Screen Sandu Pharmaceuticals income statement and profit fundamentals. Analyze SANDUPHQ quarterly results, revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Sandu Pharmaceuticals share price evaluation.
Item 2025-Mar 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec 2022-Mar 2022-Jun 2022-Sept 2022-Dec 2021-Jun 2021-Sept
Revenue 14 16 17 18 18 15 18 17 18 12 16 17 17 17 18
Expenses 14 15 17 17 17 15 17 16 17 11 16 16 16 17 17
EBITDA 1 1 0 1 1 1 0 1 1 1 0 1 1 1 1
Operating Profit % 3.00% 4.00% 2.00% 5.00% 5.00% 3.00% 2.00% 5.00% 3.00% 5.00% 2.00% 5.00% 5.00% 4.00% 5.00%
Depreciation 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 0 1 0 1 1 0 0 1 0 0 0 1 1 1 1
Tax 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Net Profit 0 1 0 1 1 0 0 1 0 0 0 1 1 0 0
EPS 0.34 0.62 0.17 1.95 0.57 0.26 0.11 0.57 0.21 0.34 0.19 0.64 0.51 0.53 0.57

Sandu Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals

Screen SANDUPHQ cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
Item 2025-March 2024-March 2023-March
Operating Activities 1 1 0
Investing Activities 0 -1 1
Financing Activities -1 -1 1
Net Cash Flow 0 -1 1

Sandu Pharmaceuticals Shareholding Pattern Screener

See Sandu Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings. Check Sandu Pharmaceuticals promoter holding and ownership changes for SANDUPHQ on TickJournal.
Item 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun
Promoter Holding 37.79% 37.79% 42.90% 42.90% 42.90% 42.90% 42.90% 42.90%
FII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
DII Holding 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 36.98% 37.01% 36.77% 36.57% 35.90% 35.34% 34.97% 44.25%
Other Holding 25.23% 25.19% 20.32% 20.53% 21.20% 21.75% 22.12% 12.84%
Shareholder Count 10,298 10,284 10,284 10,226 10,287 10,333 10,246 10,012

Sandu Pharmaceuticals Share Dividend Screener - Share Yield Analysis

Check Sandu Pharmaceuticals dividend history with payout and yield data. View Sandu Pharmaceuticals dividend details including ex-dates and amounts for SANDUPHQ stock.
Period Dividend Per Share Dividend Yield
2026-March ₹0.00 0.00%
2025-March ₹0.80 2.62%
2024-March ₹0.80 1.63%
2023-March ₹0.00 0.00%
2022-March ₹0.75 1.43%
2021-March ₹0.50 0.71%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Sandu Pharmaceuticals Stock Index Membership

See which indices include Sandu Pharmaceuticals stock. Check SANDUPHQ index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Sandu Pharmaceuticals is not part of any tracked indices.
Only major market indices are tracked in our system.

Sandu Pharmaceuticals Market Events Screener - Corporate Actions

Get Sandu Pharmaceuticals corporate actions including splits, bonuses, and buybacks. Check Sandu Pharmaceuticals stock events that may affect SANDUPHQ share price.
Announcement Date Record Date Event Type Information Price Impact
Dividend ₹ 0.80 /share -12.97%
Dividend ₹ 0.75 /share 5.08%
Dividend ₹ 0.75 /share 41.02%
Dividend ₹ 0.80 /share 4.55%
Annual General Meeting NA 3.42%
Dividend ₹ 0.50 /share 0.87%
Annual General Meeting NA -3.84%
2026-05-05 2026-05-05 Quarterly Result Announcement NA -1.85%
2026-02-06 2026-02-06 Quarterly Result Announcement NA 2.05%
2025-11-12 2025-11-12 Quarterly Result Announcement NA -2.51%
2025-08-13 2025-08-13 Quarterly Result Announcement NA 0.76%
2025-05-28 2025-05-28 Quarterly Result Announcement NA 4.41%
2025-02-13 2025-02-13 Quarterly Result Announcement NA -3.54%
2024-11-14 2024-11-14 Quarterly Result Announcement NA 2.33%

Sandu Pharmaceuticals Competitors Screener - Peer Comparison

Screen SANDUPHQ competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 450,643 40.81 54,729 9.71% 10,980 64.89
Divis Laboratories 179,470 74.13 9,712 18.67% 2,191 64.06
Torrent Pharmaceuticals 149,109 65.68 11,539 6.99% 1,911 58.52
Cipla 115,682 30.09 27,712 -2.46% 3,783 69.78
Dr Reddys Laboratories 111,567 26.16 33,593 -0.44% 3,998 59.87
Lupin 104,032 19.28 27,488 19.98% 5,345 46.11
Mankind Pharma 103,325 56.36 12,744 20.90% 2,007 73.37
Zydus Life Science 101,801 19.85 23,511 18.55% 4,615 69.47
Aurobindo Pharma 87,806 25.16 32,346 9.43% 3,484 73.83
Laurus Labs 71,455 79.78 6,813 21.03% 884 80.26

Sandu Pharmaceuticals Company Announcements - News Screener

Screen SANDUPHQ latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
Date Update Actions
2026-05-14 Announcement Under Regulation 30-Update Demand Order From Office Of Assistant Commissioner Jurisdiction Sector 3 (Mobile Squad-1) Shamli State/UT Uttar Pradesh For Detention Of Conveyance & Goods Due To Discrepancy In Quantity As Per Invoice & Quantity As -
2026-05-14 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-05-12 Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 -
2026-05-12 Statement Of Deviation And Variation Of Funds For Q Ended 31.03.2026 -
2026-05-12 Announcement under Regulation 30 (LODR)-Change in Management -
2026-05-12 Corporate Action-Board approves Dividend -
2026-05-12 Audited Financials For The Q And Year Ended 31.03.2026 -
2026-05-12 Board Meeting Outcome for Outcome Of The Board Meeting Dated 05Th May 2026 -
2026-04-27 Corporate Action-Board to consider Dividend -
2026-04-27 Board Meeting Intimation for 1.Approval Of The Audited Financial Results For The Q And Year Ended 31.03.2026 2.To Recommend Final Dividend If Any. -
2026-04-20 Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A -
2026-04-07 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-04-04 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-03-21 Closure of Trading Window -
2026-02-07 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-02-07 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-02-06 Statement Of Deviation And Variation For The Q Ended 31.12.2025 -
2026-02-06 Unaudited Financials For Quarter And Period Ended 31St December 2025 -
2026-02-06 Board Meeting Outcome for Outcome Of The Board Meeting -
2026-01-24 Board Meeting Intimation for Approval Of Unaudited Financial Results For Q Ended 31St December 2025 -